José Germán
Sánchez Hernández
Profesor Asociado CC. Salud
Publikationen (16) Publikationen von José Germán Sánchez Hernández
2024
-
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis
Gastroenterologia y Hepatologia, Vol. 47, Núm. 5, pp. 522-552
-
Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size
JCI Insight, Vol. 9, Núm. 16
2023
-
Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
Pharmacological Research
-
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
Pharmacological Research, Vol. 194
2022
-
Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease
European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 222-227
-
Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients
European Journal of Pharmaceutical Sciences, Vol. 168
2021
-
Comparison of ultra-performance liquid chromatography and ARK immunoassay for therapeutic drug monitoring of voriconazole
Annals of Clinical Biochemistry, Vol. 58, Núm. 6, pp. 657-660
-
Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease
British Journal of Clinical Pharmacology, Vol. 87, Núm. 2, pp. 447-457
-
Relación entre las concentraciones séricas de vedolizumab en fase de inducción y respuesta temprana y mantenida en el primer año de tratamiento en pacientes con colitis ulcerosa
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 7, pp. 38-44
2020
-
A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease
British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1165-1175
-
Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease
European Journal of Pharmaceutical Sciences, Vol. 150
-
Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease
Journal of pediatric gastroenterology and nutrition, Vol. 71, Núm. 4, pp. 508-515
2019
-
Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases
Annals of Clinical Biochemistry, Vol. 56, Núm. 1, pp. 28-41
2018
-
Diseño de un modelo poblacional para la monitorización farmacocinética de infliximab en enfermedad inflamatoria intestinal
Farmajournal, Vol. 3, Núm. 1, pp. 77-85
-
Study of fall risk-increasing drugs in elderly patients before and after a bone fracture
Postgraduate Medical Journal, Vol. 94, Núm. 1108, pp. 76-80
2017
-
Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia
Expert Review of Clinical Pharmacology, Vol. 10, Núm. 8, pp. 911-917